In the REaCT-Vascular Access Trastuzumab study (REaCT-VA), the investigator will use a novel method to allow comparisons of established standard of care vascular access strategies using the "integrated consent model" as part of a pragmatic clinical trial. The investigator wishes to address a non-pharmacologic issue regarding standard of care vascular access devices. Peripherally inserted central catheters (PICC lines) versus subcutaneously implanted devices (PORTs).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
56
Participants will be randomized to a PICC for vascular access during chemotherapy.
Participants will be randomized to a PORT for vascular access during chemotherapy
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Accrual rates
Percentage of patients who receive (neo)adjuvant IV systemic therapy with trastuzumab compared to the number of participants who agree to randomization.
Time frame: one year
Patient compliance
Percentage of participants who are randomized who accept randomization will be calculated.
Time frame: One year
Physician engagement
Percentage of medical oncologists who have agreed to participate in the trial compared to the percentage who approached patients regarding the trial.
Time frame: One year
Rates of events
Rates of documented thrombotic events, need for anticoagulation, line infections, phlebitis, and extravasations during systemic therapy.
Time frame: One year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.